We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





COVID-19 Antibody Test Results May Vary Based on Gender, New Study Suggests

By LabMedica International staff writers
Posted on 20 Apr 2021
A study suggests that clinical laboratories should anticipate gender-dependent differences in COVID-19 antibody levels as the findings showed these levels are significantly higher in males and that antibodies may last for four times longer in males.

The study by researchers at Cardiff Metropolitan University (Cardiff, UK) aimed to determine the antibody prevalence in a professional Welsh cohort and begin to explore the longevity of COVID-19 antibodies. More...
739 University staff members took part in the observational study to determine the prevalence of COVID-19 antibodies in a two-phase, single cohort study. All the participants were tested for IgM and IgG antibodies against COVID-19 using a lateral flow detection assay. Venous blood samples from positive participants and a randomly selected negative population were collected to confirm antibody titre, using two gold standard immunoassays.

The researchers found that 3.65% of the population tested positive for anti-bodies against COVID-19, with a higher prevalence seen in male participants (5% vs. 2.73% of females). In addition to gender, both pre-existing asthma and age were key determinants in antibody positivity. 78.26% retained antibodies at the three months follow up test. 36.36% of females lost antibody positivity between the three and six months time points compared with 8.3% of males. Lateral flow antibody testing was shown to have 96% sensitivity and 95% specificity compared with standard tests.

The researchers concluded that the prevalence of COVID-19 antibodies is evident in the asymptomatic population, and in 78.26% of those initially antibody positive prevails at approximately six months from perceived time of exposure. Additionally, males are four times more likely to retain antibodies for longer than females, making it important for clinical laboratories to recognize that COVID-19 test results may vary based on gender.

Related Links:
Cardiff Metropolitan University


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated PCR Setup
ESTREAM
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.